Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders

Pediatric Drugs

Volumn 16, Issue 4, 2014, Pages 275-291

  Ng, J ^a,b   Heales, S J R ^c,d   Kurian, M A ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Neurology Department   (United Kingdom)

^c Clinical Chemistry   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; ADRENALIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ARIPIPRAZOLE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BROMOCRIPTINE; CABERGOLINE; DIHYDROPTERIDINE REDUCTASE; DOPAMINE; DOPAMINE RECEPTOR; ENTACAPONE; FOLIC ACID; FOLINIC ACID; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; MONOAMINE; MONOAMINE DERIVATIVE; NEUROTRANSMITTER; NORADRENALIN; PERGOLIDE; PRAMIPEXOLE; PYRIDOXINE; ROPINIROLE; SELEGILINE; SEPIAPTERIN REDUCTASE; SEROTONIN; TETRAHYDROBIOPTERIN; TYROSINE 3 MONOOXYGENASE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CATECHOLAMINE;

AUTOSOMAL DOMINANT INHERITANCE; CEREBRAL PALSY; CEREBROSPINAL FLUID ANALYSIS; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE COURSE; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME THERAPY; FOLIC ACID DEFICIENCY; HUMAN; HYPERPHENYLALANINEMIA; HYPOXIC ISCHEMIC ENCEPHALOPATHY; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEROTONIN METABOLISM; SYNAPTOSOME; CHILD; METABOLISM; NERVOUS SYSTEM DISEASES; PHENYLKETONURIAS; PHYSIOLOGY;

CATECHOLAMINES; CHILD; DOPAMINE; FOLIC ACID; HUMANS; NERVOUS SYSTEM DISEASES; NEUROTRANSMITTER AGENTS; PHENYLKETONURIAS; SEROTONIN;

EID: 84905560981     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-014-0079-z     Document Type: Review

References (79)

1. Goldstein DS. Catecholamines in the periphery. Overview Adv Pharmacol. 1998;42:629-39.
2. Yildiz O, Smith JR, Purdy RE. Serotonin and vasoconstrictor synergism. Life Sci. 1998;62:1723-32. (Pubitemid 28189408)
3. Fernandez-Alvarez E. Movement disorders in children: recent advances in management. Indian J Pediatr. 2009;76:531-6.
4. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-508.
5. Friedman J, Roze E, Abdenau JE, et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol. 2012;71:520-30.
6. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmcol Sci. 1994;15:264-70. (Pubitemid 24210734)
7. Westlund KN. The distribution of monoamine oxidases A and B in normal human brain. In: Leiberman A, Olanow CW, Youdim MBH, Tipton K, editors. Monoamine oxidase inhibitors in neurological disease. New York: Marcel Dekker; 1994. p. 1-20.
8. Manegold C, Hoffmann GF, Degen I, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow up. J Inherit Metab Dis. 2009;32:371-80.
9. Bobo WV, Shelton RC. Efficacy, safety and tolerability of SymbyaxAR for acute-phase management of treatment-resistant depression. Expert Rev Neurother. 2010;10:651-70.
10. Allen GF, Land JM, Heales SJR. A new perspective on the treatment of aromatic l-amino acid decarboxylase deficiency. Mol Genet Metab. 2009;97:6-14.
11. Grapp M, Just IA, Linnankivi T, et al. Molecular characterization of folate receptor 1 mutations delineates cerebral folate transport deficiency. Brain. 2012;135(Pt 7):2022-31.
12. Porta F, Mussa A, Concolino D, et al. Dopamine agonists in dihydropteridine reductase deficiency. Mol Genet Metab. 2012;105:582-4.
13. Chang YT, Sharma R, Marsh JL, et al. Levodopa responsive aromatic L-amino acid decarboxylase deficiency. Ann Neurol. 2004;55:435-8. (Pubitemid 38269598)
14. Surtees R, Hyland K. L-3,4-dihydroxyphenylalanine (Levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans. J Neurol Neurosurg Psychiatry. 1990;53:569-72. (Pubitemid 20240008)
15. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet Neurol. 2010;376:1417-27.
16. Segawa M. Autosomal dominant GTP cyclohydrolase 1 (AD GCH1) deficiency (Segawa disease, dystonia 5, DYT 5). Chang Gung Med J. 2009;32:1-11.
17. Furukawa Y, Pagon RA, Adam MP, et al. GTP cyclohydrolase 1-deficient dopa-responsive dystonia. Gene reviews. Seattle: University of Washington; 1993-2013.
18. Segawa M. Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev. 2011;22:195-201.
19. Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol. 1976;14:215-33.
20. Trender-Gerhard I, Sweeney MG, et al. Autosomal-dominant GTPCH1-deficiency DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry. 2009;80:839-45.
21. Lee JH, Ki CS, Kim DS, et al. Dopa-responsive dystonia with a novel initiation mutation in the GCH1 gene misdiagnoses as cerebral palsy. J Korean Med Sci. 2011;26:1244-6.
22. Jan MMS. Misdiagnosis in children with Dopa responsive dystonia. J Pediatr Neurol. 2004;31:298-303. (Pubitemid 39298460)
23. Dale RC, Melchers A, Fung VS, et al. Familial paroxysmal exercise-induced dystonia: atypical presentation of autosomal dominant GTP-cyclohydrolase 1 deficiency. Dev Med Child Neurol. 2010;52:583-6.
24. Saunders-Pullman R, Blau N, Hyland K, et al. Phenylalanine loading as a diagnostic test for DRD interpreting the utility of the test. Mol Genet Metab. 2004;83:207-12. (Pubitemid 39473062)
25. Kurian MA, Gissen P, Smith M, et al. The monoamine neuro-transmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 2011;10:721-33.
26. Lopez-Laso E, Beyer K, Opladen T, et al. Dyskinesias as a limiting factor in the treatment of Segawa disease. Pediatr Neurol. 2012;46:404-6.
27. Hwang WJ, Calne JKC, Tsui R, et al. The long-term response to levodopa in dopa-responsive dystonia. Parkinson Relat Disord. 2008;8:1-5.
28. Sumi-Ichinose C, Urano F, Kuroda R, et al. Catecholamines and serotonin are differently regulated by tetrahydrobiopterin. A study from 6-pyruvolytetrahydrobiopterin synthase knockout mice. J Biol Chem. 2001;276:41150-60.
29. Bonafe L, Thony B, Leimbacjer W, et al. Diagnosis of doparesponsive dystonia and other tetrahydrobiopterin disorders by the study of biopterin metabolism in fibroblasts. Clin Chem. 2001;47:477-85. (Pubitemid 32222462)
30. Horvath GA, Stockler-Ipsiroglu SG, Salvarinova-Zivkovi R, et al. Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: Evident of a phenotypic continuum between dominant and recessive forms. Mol Genet Metab. 2008;94:127-31.
31. Opladen T, Hoffmann G, Horster F, et al. Clinical and biochemical characterisation of patients with early infantile onset of autosomal recessive GTP cyclohydrolase 1 deficiency without hyperphenylalaninemia. Mov Disord. 2011;25:157-61.
32. Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis. 2009;32:333-42.
33. Opladen T, Hoffmann GF, Blau N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inherit Metab Dis. 2012;35:963-73.
34. Smith I, Dhondt JL. Birthweight in patients with defective biopterin metabolism. Lancet. 1983;33:2417-24.
35. Leuzzi V, Carducci CA, Carducci CL, et al. Phenotypic variability, neurological outcome and genetic background of 6-pyruvoyl-tetrahydrobiopterin synthase deficiency. Clin Genet. 2010;26:157-61.
36. Jaggi L, Zurfluh MR, Schuler A, et al. Outcome and long term follow up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab. 2008;93:295-305. (Pubitemid 351200586)
37. Porta F, Mussa A, Concolino D, et al. Dopamine agonists in 6-pyruvoyl tetrahydrobiopterin synthase deficiency. Neurology. 2009;73:633-6.
38. Dill P, Wagner M, Somerville A, et al. Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency. Neurology. 2012;31(78):29-32.
39. Neville BG, Parascandalo R, Farrugia R, et al. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain. 2005;128:2291-6. (Pubitemid 41407969)
40. Friedman J, Hyland K, Blau N, et al. Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency. Neurology. 2006;67:2032-5. (Pubitemid 44967384)
41. Crabtree MJ, Tatham Al, Al Wakeel Y, et al. Quantitative regulation of intracellular endothelila nitric-oxide synthase (eNOS) coupling by tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP-cyclohydroxylase I expression. J Biol Chem. 2009;294:1136-44.
42. Willemsen MA, Verbeek MM, Kamsteeg EJ, et al. Tyrosine hydroxylase deficiency; a treatable disorder of brain catecholamine biosynthesis. Brain. 2010;133:1810-22.
43. Pons R, Syrengelas D, Syrengelas A, et al. Tyrosine hydroxylase: the Greek experience. Eur J Paediatr Neurol. 2013;15(Suppl 1):S19-20.
44. Pons R, Syrengelas D, Youroukos S, et al. Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord. 2013;28:1058-63.
45. Brun L, Ngu LH, Chang GS, et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology. 2010;75:64-71.
46. Pons R, Ford B, Chiriboga CA, et al. Aromatic amino acid decarboxylase deficiency: clinical features, treatment, prognosis. Neurology. 2004;62:1058-65. (Pubitemid 38456497)
47. Lee H, Tsai CR, Chi CS, et al. Aromatic L-amino acid decarboxylase deficiency in Taiwan. Eur J Paediatr Neurol. 2009;13:135-40.
48. Mastrangelo M, Caputi C, Galosi S, et al. Transdermal rotigotine in the treatment of aromatic L-amino acid decarboxylase deficiency. Mov Disord. 2012;28:556-7.
49. Allen GF, Neergheen V, Oppenheim M, et al. Pyridoxal 50 phosphate deficiency causes a loss of aromatic L-amino acid decarboxylase in patient and human neuroblastoma cells, implications for aromatic L-amino acid decarboxylase and vitamin B6 deficiency states. J Neurochem. 2010;114:87-96.
50. Hyland K, Surtees RAH, Rodeck C, et al. Aromatic l-amino acid decarboxylase deficiency: clinical features, diagnosis and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology. 1992;42:1980-8.
51. Maller A, Hyland K, Milstein S, et al. Aromatic L-amino acid decarboxylase deficiency: clinical feature. J Child Neurol. 1997;12:349-54.
52. Matsuda N, Hayaashi H, Miyatake T, et al. Instability of the apo form of aromatic a L-amino acid decarboxylase activity in vivo and in vitro: implications for the involvement of the flexible loop that covers the active site. J Biochem. 2004;135:33-42. (Pubitemid 38405159)
53. Swodoba KJ, Saul JP, McKenna CE, et al. Aromatic l-amino acid decarboxylase deficiency overview of clinical features and outcomes. Ann Neurol. 2003;54:264-70.
54. Paterson IA, Juorio AV, Berry MY, et al. Inhibition of mono-amine oxidase-B by deprenyl potentials neuronal response to dopamine agonistics but does not inhibit dopamine catabolism in the rat striatum. J Pharmacol Exp Ther. 1991;258:1019-26.
55. Cho AM, Duchemin NH, Neff M, et al. Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A. Eur J Pharmacol. 1996;310:51-9.
56. Dyck LE, Dewar KM. Inhibition of aromatic l-amino decarboxylase and tyrosine aminotransferase by the monoamine oxidase inhibitor phenelzine. J Neurochem. 1986;46:1899-903. (Pubitemid 16095499)
57. Hwu WL, Muramatsu S, Tseng SH, et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med. 2012;4:134ra61.
58. Mills PB, Footitt EJ, Mills KA, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain. 2010;133:218-59.
59. Mills PB, Surtees RA, Champion MP, et al. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 50 phosphate oxidase. Hum Mol Genet. 2005;14:1077-86. (Pubitemid 40575883)
60. Reddy SD, Rayala SK, Ohshiro K, et al. Multiple coregulatory control of tyrosine hydroxylase gene transcription. Proc Natl Acad Sci USA. 2011;108:4200-5.
61. Hwang DY. 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J Neurosci. 2005;25:2132-7.
62. Hwang D-Y, Ardayfio P, Kang UJ, Semina EV, Kim KS. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res. 2003;114:123-31. (Pubitemid 36773553)
63. Katarzyna Derwinska K, Mierzewska H, Goszczanska A, et al. Clinical improvement of the aggressive neurobehavioral phenotype in a patient with a deletion of PITX3 and the absence of L-DOPA in the cerebrospinal fluid. Am J Med Genet B Neuropsychiatr Genet. 2012;159:236-42.
64. Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine - serotonin vesicular transport disease and its treatment. NEJM. 2013;368:543-50.
65. Kurian MA, Zhen J, Cheng SY, et al. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism dystonia. J Clin Invest. 2009;119:1595-603.
66. Kurian MA, Li Y, Zhen J, et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol. 2011;10:54-62.
67. Ng J, Zhen J, Meyer E, et al. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain. 2014;137:1107-19.
68. Henriksen FH, Yasmeen S, Skjørringe T, et al. Atypical dopamine transporter deficiency syndrome in an adult male: molecular characterisation of new transporter variants. Program No.10.11. 2013 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience; 2013. http://www.sfn.org/&z.ast;/ media/SfN/Documents/AnnualMeeting/FinalProgram/FullAbstractPDFs/ AbstractPDFs-Nano.ashx (Online).
69. García-Cazorla A, Serrano M, Pérez-Dueñas B, et al. Secondary abnormalities of neurotransmitters in infants with neurological disorders. Dev Med Child Neurol. 2007;49:740-4.
70. Kurian MA. What is the role of dopamine in childhood neurological disorders? Dev Med Child Neurol. 2013;55(6):493-4.
71. Ng J, Tuschl K, Kinali M, et al. TH gene-negative infantile onset severe dopamine deficiency syndrome: a novel neurotransmitter disorder? Dev Med Child Neurol. 2013;5(S1):15.
72. Breakfield XO, Blood A, Li Y, et al. The pathophysiological basis of dystonias. Nat Rev Neurosci. 2008;9:222-43.
73. Bhidayasiri R, Tarsay D. Treatment of dystonia. Expert Rev Neurother. 2006;6:863-86. (Pubitemid 43961888)
74. Lopez-Laso E, Ochoa-Sepulveda JJ, Ochoa-Amor JJ, et al. Segawa syndrome due to mutation Q89X in the GCH1 gene: a possible founder effect in Cordoba (southern Spain). J Neurol. 2009;256:1816-24.
75. Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol. 1984;20:425-30. (Pubitemid 14064081)
76. Liow N, Marianczak J, Kirk E. et al. Gabapentin can improve dystonia severity, transfers, sitting, sleep, mood and pain in children EJPN. 2013;S18:O58-2017.
77. Brasil S, Viecelli HM, Meili D, et al. Pseudoexom exclusion by antisense therapy in 6-pyruvoyl-tetrahydrobiopterin synthase deficiency. Hum Mutat. 2011;32:1019-27.
78. Jatana N, Apoorva N, Malik S, et al. Inhibitors of catechol- O-methyl transferase in the treatment of neurological disorders. Central Nerv Syst Agents Med Chem. 2014;2013(13):166-94.
79. Eberling JL, Jaqust WJ, Christine CW, et al. Results from phase 1 safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008;80:1980-3.